Clinical Study of Asciminib in Previously Treated Indian Patients With Ph+ CML-CP Without T315I Mutation and in Patients With Ph+ CML-CP With T315I Mutation

Clinical trial NCT06427811 · COMPLETED

Trial details

NCT number: NCT06427811
Sponsor: Novartis Pharmaceuticals
Status: COMPLETED
Phase: Phase 4
Study type: INTERVENTIONAL

Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase

Start date: 2024-11-28
Primary completion: 2026-03-18
Enrollment: 85

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.